Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. Our lead clinical asset, M207, has completed the pivotal ZOTRIP trial. Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies.
Therapeutic blood levels obtained more rapidly than with oral administration.
Ready. Set. Apply. Three easy steps for administration.
We use known therapeutics with well-established safety and efficacy profiles.
Zosano Pharma’s investigational migraine treatment, ADAM Zolmitriptan (M207), is a novel formulation of zolmitriptan, a drug used orally and nasally to effectively and safely treat migraines, administered via the Company’s proprietary intracutaneous delivery system. ADAM Zolmitriptan (M207) is being investigated as a potential treatment to provide rapid relief of migraine symptoms, at any time in the migraine cycle, in a discreet and simple manner.